

Corporate-Sponsored Presentations

Session Time (CST)	Abstract No./Title/Lead Author	Session Type/Category/Title
<p>Tuesday, December 6, 2022 5:00 PM-6:15 PM</p>	<p>OT1-03-06 / Ladiratumab Vedotin SGN-LVA-002 TIP Phase 1b/2 study of ladiratumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (SGNLVA-002, trial in progress) Lead Author: Patrick Dillon</p>	<p>Poster Presentation Ongoing Trials Poster Session 1: Antibody-Drug Conjugates</p>
<p>Wednesday, December 7, 2022 5:00 PM-6:15 PM</p>	<p>OT2-16-03 / Tucatinib HER2CLIMB-05 TIP Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress) Lead Author: Erika Hamilton</p>	<p>Poster Presentation Ongoing Clinical Trials Poster Session 2: Monoclonal Antibodies</p>
<p>Thursday, December 8, 2022 7:00 AM-8:15 AM</p>	<p>P4-03-30 / Tucatinib HEOR Patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer Lead Author: Peter A. Kaufman</p>	<p>Poster Presentation Epidemiology, Risk, and Prevention Poster Session 4: Epidemiology-Population Studies</p>

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Session Time (CST)	Abstract No./Title/Lead Author	Session Type/Category/Title
Tuesday, December 6, 2022 5:00 PM-6:15 PM	OT1-10-01 / Tucatinib InTTercePT TIP Treatment with tucatinib in addition to pertuzumab and trastuzumab in patients with HER2-positive metastatic breast cancer (HER2+ MBC) after local therapy of isolated brain progression: InTTercePT, a UCBG/GINECO study Lead Author: Thomas Bachelot	Poster Presentation Ongoing Clinical Trials Poster Session 2: Brain Metastases
Thursday, December 8, 2022 5:00 PM-6:15 PM	OT3-09-01 / Tucatinib TUC-IST-2020-102641 TIP Clinical trial of alpelisib and tucatinib in patients with PIK3CAmMutant HER2-positive metastatic breast cancer Lead Author: Elena Shagisultanova	Poster Presentation Ongoing Clinical Trials Poster Session 3: PI3K Mutants-Overcoming Resistance

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.